Xiromed unveils generic Extina
The medication is the generic of Extina, which is used to treat a certain skin conditions, including seborrheic dermatitis.
Xiromed, a division of Insud Pharmaceuticals, is debuting ketoconazole foam, 2%.
The medication is the generic of Extina, and is used to treat a certain skin condition (seborrheic dermatitis).
“This is an exciting day for Xiromed as we launch our first foam product in the U.S. market. Xiromed is focused on expanding the range of dosage forms offered in our portfolio, and the launch of ketoconazole foam, 2% demonstrates our commitment to expansion into a wide variety of dosage forms, in order to drive value for our customers,” said Xiromed CEO, Narasimhan Mani.
Extina and its generics had a market value of $6.2 million for the 12 month period ended April 2021, according to IQVIA.